相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma
Jing Shen et al.
MODERN PATHOLOGY (2020)
Degradation of proteins by PROTACs and other strategies
Yang Wang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
Lara Mussolin et al.
CANCERS (2020)
High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells
Domenico Sorrentino et al.
CANCERS (2020)
ALK-transformed mature T lymphocytes restore early thymus progenitor features
Annabelle Congras et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
Yuanyuan Sun et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells
Coralie Hoareau-Aveilla et al.
HAEMATOLOGICA (2019)
Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management
Jasmine M. Zain
AMERICAN JOURNAL OF HEMATOLOGY (2019)
ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients
David Sibon et al.
HAEMATOLOGICA (2019)
A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening
Jing-Ping Zhang et al.
BLOOD (2019)
NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
Vijay Kumar Singh et al.
ONCOIMMUNOLOGY (2019)
The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
Stephen P. Ducray et al.
CANCERS (2019)
Efficacy of nivolumab in a patientwith systemic refractory ALK plus anaplastic large cell lymphoma
Charlotte Rigaud et al.
PEDIATRIC BLOOD & CANCER (2018)
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer
Benjamin J. Solomon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Role and targeting of anaplastic lymphoma kinase in cancer
Carminia Maria Della Corte et al.
MOLECULAR CANCER (2018)
ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells
Andrey Fadeev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells
Annabelle Congras et al.
Oncotarget (2018)
The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
Ivonne A. Montes-Mojarro et al.
CANCERS (2018)
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Geeta Geeta Sharma et al.
CANCERS (2018)
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Chung Hyo Kang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Tammy Linlin Song et al.
BLOOD (2018)
Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma
Fabian Knoerr et al.
CLINICAL IMMUNOLOGY (2018)
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies
Fausto Petrelli et al.
PLOS ONE (2018)
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
Eva M. Donato et al.
ONCOTARGETS AND THERAPY (2018)
Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma
Lara Mussolin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
ALK gene alterations in cancer: biological aspects and therapeutic implications
Raffaele Palmirotta et al.
PHARMACOGENOMICS (2017)
Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas
Coralie Hoareau-Aveilla et al.
CANCERS (2017)
Strategies and Approaches of Targeting STAT3 for Cancer Treatment
Stefanie L. Furtek et al.
ACS CHEMICAL BIOLOGY (2016)
Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety
Thomas S. Y. Chan et al.
ANNALS OF HEMATOLOGY (2016)
Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
Holger Hebart et al.
ANNALS OF INTERNAL MEDICINE (2016)
Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8+ T cell responses in children with NPM-ALK+ anaplastic large cell lymphoma
V. K. Singh et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress
Tim I. M. Malcolm et al.
NATURE COMMUNICATIONS (2016)
Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling
Melanie R. Hassler et al.
CELL REPORTS (2016)
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies
Francesca Casaluce et al.
CURRENT CLINICAL PHARMACOLOGY (2016)
Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial
Byeong-Bae Park et al.
ANNALS OF HEMATOLOGY (2015)
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Frederick H. Wilson et al.
CANCER CELL (2015)
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
Irina Lambertz et al.
CLINICAL CANCER RESEARCH (2015)
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth
Coralie Hoareau-Aveilla et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
Thomas Wiesner et al.
NATURE (2015)
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
Phillip B. Murray et al.
SCIENCE SIGNALING (2015)
Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors
A. Aubry et al.
CELL DEATH & DISEASE (2015)
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
Phillip B. Murray et al.
SCIENCE SIGNALING (2015)
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma
Christine Damm-Welk et al.
BLOOD (2014)
STAT3-mediated activation of microRNA cluster 17∼92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma
Elisa Spaccarotella et al.
HAEMATOLOGICA (2014)
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
Daria Zdzalik et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients
Carlo Gambacorti Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
The Potent Oncogene NPM-ALK Mediates Malignant Transformation of Normal Human CD4+ T Lymphocytes
Qian Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Monica Ceccon et al.
MOLECULAR CANCER RESEARCH (2013)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
L. Mussolin et al.
LEUKEMIA (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Bengt Hallberg et al.
NATURE REVIEWS CANCER (2013)
MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression
Deeksha Vishwamitra et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
ALK signaling and target therapy in anaplastic large cell lymphoma
Fabrizio Tabbo et al.
FRONTIERS IN ONCOLOGY (2012)
ALK inhibitors, a pharmaceutical perspective
Elena Ardini et al.
FRONTIERS IN ONCOLOGY (2012)
ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers
Anton Wellstein
FRONTIERS IN ONCOLOGY (2012)
MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression
Cecile Desjobert et al.
BLOOD (2011)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
NPM1/B23: AMultifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling
Mikael S. Lindstrom
BIOCHEMISTRY RESEARCH INTERNATIONAL (2011)
Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk
Kamel Ait-Tahar et al.
BLOOD (2010)
Matrix Metalloproteinase-9 Is Upregulated in Nucleophosmin-Anaplastic Lymphoma Kinase-Positive Anaplastic Lymphomas and Activated at the Cell Surface by the Chaperone Heat Shock Protein 90 to Promote Cell Invasion
Frederic Lagarrigue et al.
CANCER RESEARCH (2010)
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
James E. Butrynski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Anaplastic Lymphoma Kinase-Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis
Camille Laurent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
STAT3 as a target for inducing apoptosis in solid and hematological tumors
Khandaker Al Zaid Siddiquee et al.
CELL RESEARCH (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein
Mitsuru Okuwaki
JOURNAL OF BIOCHEMISTRY (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
ALK is a novel dependence receptor - Potential implications in development and cancer
Michele Allouche
CELL CYCLE (2007)
Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf
M. Marzec et al.
ONCOGENE (2007)
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression
Georglos V. Georgakis et al.
EXPERIMENTAL HEMATOLOGY (2006)
Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage
Jaouhar Mourali et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Francisco Vega et al.
CANCER RESEARCH (2006)
New and old functions of STAT3 - A pivotal target for individualized treatment of cancer
G Inghirami et al.
CELL CYCLE (2005)
Biological role of anaplastic lymphoma kinase in neuroblastoma
Y Osajima-Hakomori et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
R Chiarle et al.
NATURE MEDICINE (2005)
The emerging normal and disease-related roles of anaplastic lymphoma kinase
K Pulford et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
Anaplastic lymphoma kinase proteins in growth control and cancer
K Pulford et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: Role of the co-chaperone carboxyl heat shock protein 70-interacting protein
P Bonvini et al.
CANCER RESEARCH (2004)
Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: A study of 135 cases
MH Cessna et al.
MODERN PATHOLOGY (2002)
Translocations involving anaplastic lymphoma kinase (ALK)
J Duyster et al.
ONCOGENE (2001)
Identification and characterization of DAlk:: a novel Drosophila melanogaster RTK which drives ERK activation in vivo
CE Lorén et al.
GENES TO CELLS (2001)
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
RY Bai et al.
BLOOD (2000)
Expression of the ALK tyrosine kinase gene in neuroblastoma
L Lamant et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children - A report from the French Society of Pediatric Oncology
L Brugieres et al.
ANNALS OF ONCOLOGY (2000)
分享论文
